Clinical Trial Update: Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating KUC-7483 for overactive bladder has been withdrawn, ending the long-term safety and efficacy assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• KUC-7483

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Overactive Bladder | Phase 3 | Status: WITHDRAWN